Document is current
Any future updates will be listed below
-
Authors
Taylor, Jonathan D. https://orcid.org/0000-0002-9797-3989
Barrett, Nathalie
Martinez Cuesta, Sergio https://orcid.org/0000-0001-9806-2805
Cassidy, Katelyn https://orcid.org/0000-0002-4487-0011
Pachl, Fiona
Dodgson, James
Patel, Radhika
Eriksson, Tuula M.
Riley, Aidan
Burrell, Matthew
Bauer, Christin https://orcid.org/0000-0003-3466-7076
Rees, D. Gareth https://orcid.org/0000-0002-4268-6018
Cimbro, Raffaello
Zhang, Andrew X.
Minter, Ralph R.
Hunt, James https://orcid.org/0000-0002-3144-3467
Legg, Sandrine
- License Information
-
More Information
Article History
Received: 8 March 2024
Accepted: 29 August 2024
First Online: 19 September 2024
Competing interests
: All authors are present, or former employees of AstraZeneca. J.D.T., T.M.E., S.M.C., A.R., C.B., N.B., J.H., R.M., M.B., F.P., R.C., D.G.R., A.Z., and J.D. hold AstraZeneca stock. R.M. and S.L. are employees of Alchemab Therapeutics, Cambridge, UK. K.C. is an employee of C4 Therapeutics, Watertown, MA, USA. This work is related to patent WO2022106869A1<sup>21</sup>.
